当前位置:

网站首页>文章详情

匹伐他汀联合乙酰半胱氨酸对经皮冠脉介入诊疗术患者对比剂肾病的治疗研究

【PDF在线阅读】 【下载PDF】
  • Author:

  • Author Unit:

  • Keywords:

摘要:

目的 探讨常规剂量匹伐他汀钙片联合乙酰半胱氨酸对经皮冠状动脉介入治疗(PCI)后对
比剂肾病(CIN)预防作用及可能的作用机制。方法 选取2017年10月至2018年10月于保定市第一医院心
内科择期行PCI的126例冠心病患者为研究对象,按照随机数字表法分为3组:对照组(A组,n=42)、常
规剂量匹伐他汀组(B组,n=42)、常规剂量匹伐他汀联合乙酰半胱氨酸组(C组,n=42)。所有患者术
前,术后24 h及72 h均抽取外周静脉血检测血肌酐(Scr)、丙二醛(MDA)及超氧化物歧化酶(SOD)
水平。通过Cockcroft-Gault公式计算内生肌酐清除率(CCr)。结果 3组入选患者术前一般临床资料及生
化指标比较,差异均无统计学意义(P均>0.05)。与术前相比,术后24 h,A组Scr、MDA水平较术前
均升高(P均<0.05),CCr水平较术前降低(P<0.05)。术后72 h,A、B组Scr及MDA水平较术前均升
高(P均<0.05),CCr及SOD水平较术前均降低(P均<0.05)。与术前相比,C组术后24 h及术后72 h
时,Scr、CCr、MDA及SOD的变化均没有统计学意义(P均>0.05);A、B、C组术后 72 h CIN的发生情
况分别为7例(16.7%)、3例(7.1%)、0例(0%),C组CIN的发生率低于A组,差异有统计学意义(P
<0.05)。结论 冠状动脉介入术(冠脉造影及支架植入术)患者术前服用匹伐他汀和乙酰半胱氨酸可在
一定程度上保护肾功能,抗氧化应激可能是其主要的肾脏保护机制。

Abstract:

Objective To investigate the preventive effect of pitavastatin combined with N-acetylcysteine
(NAC) in routine dose on contrast-induced nephropathy (CIN) in patients after percutaneous coronary intervention
(PCI), and discuss possible effective mechanism. Methods The patients with coronary heart disease (CHD)
undergone PCI (n=126) were chosen from Department of Cardiology in the First Hospital of Baoding City from Oct.
2017 to Oct. 2018. All patients were divided, according to random digital table, into control group (group A, n=42),
routine-dose pitavastatin group (group B, n=42) and routine-dose pitavastatin combined with NAC group (group
C, n=42). The levels of serum creatinine (SCr), malondialdehyde (MDA) and superoxide dismutase (SOD) were
detected after collecting samples of peripheral venous blood from the patients before and after PCI for 24 h and
72 h. The endogenous creatinine clearance rate (CCr) was calculated by using Cockcroft-Gault formula. Results
The comparison in general clinical materials and biochemical indexes showed the differences had no statistical
significance among 3 groups before PCI (all P>0.05). Compared with before, the levels of Scr and MDA increased (all
P<0.05) and level of CCr decreased (P<0.05) in group A after PCI for 24 h. The levels of Scr and MDA increased
(all P<0.05) and levels of CCr and SOD decreased (all P<0.05) in groups A and B after PCI for 72 h. Compared with
before, the changes of levels of Scr, CCr, MDA and SOD had no statistical significance in group C after PCI for 24
h and 72 h (all P>0.05). There were 7 cases (16.7%) of CIN in group A, 3 (7.1%) in group B and 0 (0%) in group
C, and CIN incidence rate was lower in group C than that in group A (P<0.05). Conclusion Pitavastatin combined
with NAC taken before PCI can protect kidney function to some extent in CHD patients, and antioxidation stress
may be the mechanism of protecting kidney function.

基金项目:

河北省保定市科技发展项目(17ZF089)

参考文献:

[1] Aspelin P. Nephrotoxicity and the role of contrast media[J]. Radiat
Med, 2004,22(6):377-8.
[2] Nakamura T,Ushiyama C,Hirokawa K,et al. Effect of cenivastin
on proteinuria and urinary podocytes in patients with chronic
glomlonephntis[J]. Nephrol Dial Transplant,2002,17(5):798-802.
[3] Koc F,Ozdemir K,Kaya MG,et al. Intravenous N-acetylcysteine
plus high-dose hydration versus high-dose hydration and standard
hydration for the prevention of contrast-induced nephropathy:
CASIS-a multicenter prospective controlled trial[J]. Int J Cardiol,
2012,155(3):418-23.
[4] Liistro F,Falsini G,Bolognese L. The Clinical burden of contrastmedia-
induced nephropathy[J]. Ital Heart J,2003,4(10):668-76.
[5] Heyman SN,Rosen S,Khamaisi M,et al. Reactive oxygen species and
the pathogenesis of radiocontrast-induced nephropathy[J]. Invest
Radiol,2010,45(4):188-95.
[6] Bartorelli AL,Marenzi G. Contrast-induced nephropathy[J]. J Interv
Cardiol,2008,21(1):74-85.
[7] 孙涛,万大国,宋恒良,等. 瑞舒伐他汀对大鼠急性心肌梗死后梗死
组织miR-126的表达及血管再生的影响[J]. 郑州大学学报(医学),
2013,48(5):640-3.
[8] 何秀荣,邹定,姜文清,等. 降血脂新药匹伐他汀[J]. 中国新药杂志,
2005,14(4):483-7.
[9] Tokoro T,Wang J,Kitajima I. The novel HMG-CoA reductase inhib
itor,pitavastatin,induces a protective action in vascular endothelial
cells through the production of nitric oxide(NO)[J]. Yakugaku Zasshi,
2004,124(3):121-6.
[10] Patti G,Nusca A,Chello M,et al. Usefulness of statin pretreatment
to prevent contrast-induced nephropathy and to improve longterm
outcome in patients undergoing percutaneous coronary
intervention[J]. Am J Cardiol, 2008, 101(3):279-85.
[11] Jo SH,Koo BK,Papk JS,et al. Prevention of radiocontrast mediuminduced
nephropathy using short-term high-dose simvastatin in
patients with renal insufficiency undergoing coronary angiography
(PROMISS) trial-a randomized controlled study[J]. Am Heart J,
2008,155(3):499.e1-8.
[12] Fung JW,Szeto CC,Chan WW,et al. Effect of N-acetylcysteine for
prevention of contrast nephropathy in patients with moderate to
severe renal insufficiency: a randomized trial[J]. Am J Kidney Dis,
2004,43(5):801-8.
  • 2008

  • 1

通讯地址:北京市东城区东四十条南门仓5号
电话: 237499284 邮编:100700
网址:www.ebcvm..org Email: ebcvm_cj@126.com

copyright © 《中国循证心血管医学杂志》编辑部
当您在使用本网站投稿遇到困难时,
请直接将稿件投送到编辑部邮箱ebcvm_cj@126.com